BioCentury | Mar 16, 1998
Finance

Glaxo thinks ROI

...a contributing associate. Managing partner Sam Isaly founded OrbiMed in January after the breakup of Mehta & Isaly...
BioCentury | Jan 12, 1998
Finance

Tale of two markets

...declined to comment. WHAT ISALY IS UP TO: Samuel Isaly, a co-founder of recently dissolved Mehta & Isaly...
BioCentury | Sep 29, 1997
Finance

Ebb & Flow Focus: Summer paradox

...rotation and biotech is now the hot sector," said Sven Borho, assistant portfolio manager for Mehta & Isaly...
BioCentury | Jul 7, 1997
Finance

What doth summer bring?

...said Sven Borho, an associate portfolio manager at G\A Capital Management, the buyside arm of Mehta & Isaly...
BioCentury | Mar 24, 1997
Emerging Company Profile

Ontogeny Inc.

...raised: $41 million Investors: Greylock; Sutter Hill; Whitney; One Liberty; Charles River; Medical Science Partners; Mehta & Isaly...
BioCentury | Aug 12, 1996
Finance

Party of one

...said Sven Borho, an associate portfolio manager at G\A Capital Management, the buyside arm of Mehta & Isaly...
BioCentury | Jun 24, 1996
Finance

The 'C' word

...ITRC . . . Paul Boni left Mehta & Isaly...
...ITRC . . . Paul Boni left Mehta & Isaly...
BioCentury | Mar 18, 1996
Finance

Efficient markets?

...and prevent organ transplant rejection. Collaborative (Cleveland, Ohio) is a clinical research organization. LAST WORD: Mehta & Isaly...
BioCentury | Nov 6, 1995
Strategy

The low-ball bid for Immunex

...pivotal trials in infectious disease. IMNX's medium-term opportunity is its TNF receptor. Edmund Debler of Mehta & Isaly...
BioCentury | Jan 23, 1995
Analyst Picks & Changes

Analyst picks & changes

...if its recently announced public offering for 1 million shares is completed. Edmund Debler of Mehta & Isaly...
Items per page:
1 - 10 of 17
BioCentury | Mar 16, 1998
Finance

Glaxo thinks ROI

...a contributing associate. Managing partner Sam Isaly founded OrbiMed in January after the breakup of Mehta & Isaly...
BioCentury | Jan 12, 1998
Finance

Tale of two markets

...declined to comment. WHAT ISALY IS UP TO: Samuel Isaly, a co-founder of recently dissolved Mehta & Isaly...
BioCentury | Sep 29, 1997
Finance

Ebb & Flow Focus: Summer paradox

...rotation and biotech is now the hot sector," said Sven Borho, assistant portfolio manager for Mehta & Isaly...
BioCentury | Jul 7, 1997
Finance

What doth summer bring?

...said Sven Borho, an associate portfolio manager at G\A Capital Management, the buyside arm of Mehta & Isaly...
BioCentury | Mar 24, 1997
Emerging Company Profile

Ontogeny Inc.

...raised: $41 million Investors: Greylock; Sutter Hill; Whitney; One Liberty; Charles River; Medical Science Partners; Mehta & Isaly...
BioCentury | Aug 12, 1996
Finance

Party of one

...said Sven Borho, an associate portfolio manager at G\A Capital Management, the buyside arm of Mehta & Isaly...
BioCentury | Jun 24, 1996
Finance

The 'C' word

...ITRC . . . Paul Boni left Mehta & Isaly...
...ITRC . . . Paul Boni left Mehta & Isaly...
BioCentury | Mar 18, 1996
Finance

Efficient markets?

...and prevent organ transplant rejection. Collaborative (Cleveland, Ohio) is a clinical research organization. LAST WORD: Mehta & Isaly...
BioCentury | Nov 6, 1995
Strategy

The low-ball bid for Immunex

...pivotal trials in infectious disease. IMNX's medium-term opportunity is its TNF receptor. Edmund Debler of Mehta & Isaly...
BioCentury | Jan 23, 1995
Analyst Picks & Changes

Analyst picks & changes

...if its recently announced public offering for 1 million shares is completed. Edmund Debler of Mehta & Isaly...
Items per page:
1 - 10 of 17